GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Giant Biogene Holding Co Ltd (HKSE:02367) » Definitions » Capex-to-Operating-Income

Giant Biogene Holding Co (HKSE:02367) Capex-to-Operating-Income : 0.04 (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Giant Biogene Holding Co Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Giant Biogene Holding Co's Capital Expenditure for the six months ended in Dec. 2023 was HK$-45.36 Mil. Its Operating Income for the six months ended in Dec. 2023 was HK$1,031.22 Mil.

Hence, Giant Biogene Holding Co's Capex-to-Operating-Income for the six months ended in Dec. 2023 was 0.04.

Giant Biogene Holding Co Capex-to-Operating-Income Historical Data

The historical data trend for Giant Biogene Holding Co's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Giant Biogene Holding Co Capex-to-Operating-Income Chart

Giant Biogene Holding Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
0.17 0.09 0.12 0.13 0.14

Giant Biogene Holding Co Semi-Annual Data
Dec19 Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
Capex-to-Operating-Income Get a 7-Day Free Trial - 0.09 0.16 0.26 0.04

Competitive Comparison of Giant Biogene Holding Co's Capex-to-Operating-Income

For the Household & Personal Products subindustry, Giant Biogene Holding Co's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Giant Biogene Holding Co's Capex-to-Operating-Income Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Giant Biogene Holding Co's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Giant Biogene Holding Co's Capex-to-Operating-Income falls into.


Giant Biogene Holding Co Capex-to-Operating-Income Calculation

Giant Biogene Holding Co's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-249.855) / 1821.003
=0.14

Giant Biogene Holding Co's Capex-to-Operating-Income for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-45.361) / 1031.215
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Giant Biogene Holding Co  (HKSE:02367) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

Giant Biogene Holding Co Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Giant Biogene Holding Co's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Giant Biogene Holding Co (HKSE:02367) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Giant Biogene Holding Co Ltd (HKSE:02367) » Definitions » Capex-to-Operating-Income
Comparable Companies
HKSE:01044 HKSE:00973 HKSE:03331 HKSE:06993 HKSE:02145 HKSE:06601 HKSE:00157 HKSE:01925 HKSE:02023 HKSE:03828 PG XPAR:OR LSE:ULVR BOM:500696 CL LSE:RKT KMB EL KVUE XTER:BEI
Traded in Other Exchanges
N/A
Address
No. 1855, Shanglin Yuan 7th Road, Chang’an District, Shaanxi Province, Xi’an, CHN
Website
http://www.xajuzi.com
Giant Biogene Holding Co Ltd design, develop and manufacture professional skin treatment products with recombinant collagen as the key bioactive ingredient. The company also develops and manufactures rare ginsenosides technology-based functional foods. The company utilizes proprietary synthetic biology technology to develop and manufacture multiple types of recombinant collagen and rare ginsenosides in-house. Bioactive ingredients offer a wealth of beauty and health properties such as skin repair, anti-aging, whitening, moisturizing and immunity improvement with a broad range of applications in the beauty and health sectors.
Executives
Refulgence Holding Limited 2201 Interest of corporation controlled by you
Juzi Holding Co., Ltd 2101 Beneficial owner
Fan Daidi 2201 Interest of corporation controlled by you
Yan Jianya 2202 Interest of your spouse
Yi Fang Da Ji Jin Guan Li You Xian Gong Si 2102 Investment manager
Yan Jianya 2101 Beneficial owner
Fan Daidi
Trident Trust Company (b.v.i.) Limited 2301 Trustee

Giant Biogene Holding Co (HKSE:02367) Headlines

No Headlines